The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial
Open accessAbstract
Background Sotorasib is a specific, irreversible inhibitor of the GTPase protein, KRAS G12C. We compared the efficacy and safety of sotorasib with a standard-of-care treatment in patients with non-small-cell lung cancer (NSCLC) with the KRAS G12C mutation who had been previously treated with other anticancer drugs.Methods We conducted a randomised, open-label phase 3 trial at 148 centres in 22 countries. We recruited patients aged at least 18 years with KRAS G12C-mutated advanced NSCLC, who progressed after previous platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor. Key exclusion criteria included new or progressing untreated brain lesions or symptomatic brain lesions, previously identified oncogenic driver mutation other than KRAS G12C for which an approved therapy is available (eg EGFR or ALK), previous treatment with docetaxel (neoadjuvant or adjuvant docetaxel was allowed if the tumour did not progress within 6 months after the therapy was terminated), previous treatment with a direct KRAS G12C inhibitor, systemic anticancer therapy within 28 days of study day 1, and therapeutic or palliative radiation therapy within 2 weeks of treatment initiation. We randomly assigned (1:1) patients to oral sotorasib (960 mg once daily) or intravenous docetaxel (75 mg/m 2 once every 3 weeks) in an open-label manner using interactive response technology. Randomisation was stratified by number of previous lines of therapy in advanced disease (1 vs 2 vs >2), ethnicity (Asian vs non-Asian), and history of CNS metastases (present or absent). Treatment continued until an independent central confirmation of disease progression, intolerance, initiation of another anticancer therapy, withdrawal of consent, or death, whichever occurred first. The primary endpoint was progression-free survival, which was assessed by a blinded, independent central review in the intention-to-treat population. Safety was assessed in all treated patients. This trial is registered at ClinicalTrials.gov, NCT04303780, and is active but no longer recruiting.Findings Between June 4, 2020, and April 26, 2021, 345 patients were randomly assigned to receive sotorasib (n=171 [50%]) or docetaxel (n=174 [50%]). 169 (99%) patients in the sotorasib group and 151 (87%) in the docetaxel group received at least one dose. After a median follow-up of 17·7 months (IQR 16·4-20·1), the study met its primary endpoint of a statistically significant increase in the progression-free survival for sotorasib, compared with docetaxel (median progression-free survival 5·6 months [95% CI 4·3-7·8] vs 4·5 months [3·0-5·7]; hazard ratio 0·66 [0·51-0·86]; p=0·0017). Sotorasib was well tolerated, with fewer grade 3 or worse (n=56 [33%] vs n=61 [40%]) and serious treatment-related adverse events compared with docetaxel (n=18 [11%] vs n=34 [23%]). For sotorasib, the most common treatment-related adverse events of grade 3 or worse were diarrhoea (n= 20 [12%]), alanine aminotransferase increase (n=13 [8%]), and aspartate aminotransferase increase (n=9 [5%]). For docetaxel, the most common treatment-related adverse events of grade 3 or worse were neutropenia (n=13 [9%]), fatigue (n=9 [6%]), and febrile neutropenia (n=8 [5%]).Interpretation Sotorasib significantly increased progression-free survival and had a more favourable safety profile, compared with docetaxel, in patients with advanced NSCLC with the KRAS G12C mutation and who had been previously treated with other anticancer drugs.Funding Amgen.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical trials of multiple KRASG12C inhibitors have shown promising efficacy in advanced, previously treated non–small cell lung cancer (NSCLC), leading to United States Food and Drug Administration (FDA) accelerated approval of two of these therapies (adagrasib and sotorasib) and many others being investigated in this setting (9–17).”
From Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer (2024) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For example, sotorasib, adagrasib, and divarasib monotherapies have demonstrated objective response rates ranging from 7.1% to 53.4% and median progression-free survival of 4.0-13.1 months, 13-20”
From Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer (2024) · cites this paper as [15]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“This is further supported by a numerically higher ORR seen with divarasib in patients with non-small cell lung cancer (56.4%) compared with sotorasib (37% in a phase 2 trial and 28% in a phase 3 trial) and adagrasib (43% in a phase 2 trial)11,23–25.”
From Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial (2024) · cites this paper as [23]
The cited source says what the claim attributes to it.
In the citing paper
“while median overall survival was not improved with sotorasib compared with docetaxel (10.6 vs. 11.3 months; HR, 1.01) [25]”
From Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies (2026) · cites this paper as [25]
The cited source says what the claim attributes to it.
In the citing paper
“In the randomized phase III CodeBreaK 200 trial, sotorasib significantly improved progression-free survival compared with docetaxel in previously treated KRAS G12C-mutant NSCLC (median PFS, 5.6 vs. 4.5 months; HR, 0.66).”
From Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies (2026) · cites this paper as [25]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In addition, some patients selected for these trials may have preexisting multidrug resistance (9, 37, 74), which could contribute to treatment failure.”
From SRC kinase drives multidrug resistance induced by KRAS-G12C inhibition (2024) · cites this paper as [74]
Experimental — accuracy not yet measuredIn the citing paper
“Despite this success, disease progression occurs in many patients4,5,7, with development of resistance to KRASG12Ci recapitulated in preclinical studies9–11.”
From Co-targeting SOS1 enhances the antitumor effects of KRASG12C inhibitors by addressing intrinsic and acquired resistance (2024) · cites this paper as [5]
In the citing paper
“Multiple mechanisms of intrinsic and acquired resistance (10,12,13), have been identified; hence, drug combinations will likely be needed to maximize the clinical efficacy of G12Cis (and probably other, emerging KRAS inhibitors) in NSCLC and other diseases.”
From Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRASG12C Inhibitor Efficacy (2023) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
Hanna, N., Shepherd, F. A., Fossella, F. V., Pereira, J. R., De Marinis, F., von Pawel, J., Gatzemeier, U., Tsao, T. C. Y., Pless, M., Muller, T., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.163 · Cited by 2,426
Self-citationThe Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity
Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277
Shepherd, F. A., Dancey, J. E., Ramlau, R., Mattson, K. V., Gralla, R. J., O’Rourke, M. A., Levitan, N. I., Gressot, L., Vincent, M. D., Burkes, R. L., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.10.2095 · Cited by 2,178
Sotorasib for Lung Cancers with KRAS p.G12C Mutation
Skoulidis, F., Li, B. T., Dy, G. K., Price, T. J., Falchook, G. S., Wolf, J., Italiano, A., Schuler, M., Borghaei, H., Barlesi, F., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103695 · Cited by 1,849
Self-citationFossella, F. V., DeVore, R. F., Kerr, R. N., Crawford, J., Natale, R. R., Dunphy, F., Kalman, L. A., Miller, V. A., Lee, J. S., Moore, M., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.12.2354 · Cited by 1,360
Garon, E. B., Ciuleanu, T.-E., Arrieta, O., Prabhash, K., Syrigos, K. N., Goksel, T., Park, K., Gorbunova, V., Kowalyszyn, R. D., Pikiel, J., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60845-x · Cited by 1,309
Reck, M., Kaiser, R., Mellemgaard, A., Douillard, J.-Y., Orlov, S., Krzakowski, M., von Pawel, J., Gottfried, M., Bondarenko, I., Liao, M., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70586-2 · Cited by 951
Self-citationFirst-Line Immunotherapy for Non–Small-Cell Lung Cancer
Reck, M., Remón, J., & Hellmann, M. D. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01497 · Cited by 909
Research works printed but not linked: 1
- Awad, 2022, Sotorasib in advanced KRAS p.G12C-mutated non-small cell lung cancer (NSCLC): safety and efficacy data from the global expanded access program (EAP), Ann Oncol, 33, S448
Cited by
Sorted by citations
Items 101–200 of 619
Advances in the treatment of KRASG12C mutant non–small cell lung cancer
Shaverdashvili, K., & Burns, T. F. (2025) · Cancer · doi:10.1002/cncr.35783 · Cited by 25
D3S-001 in advanced solid tumors with KRASG12C mutations: a phase 1 trial
Cho, B. C., Lü, S., Lee, M. A., Song, Z., Park, J., Lim, S. M., Li, Z., Zhao, J., Richardson, G. E., Zhang, Y., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03688-6 · Cited by 24
Self-citationPassiglia, F., Reale, M. L., Russo, G. L., Pasello, G., Minuti, G., Bulotta, A., Galetta, D., Pelizzari, G., Sini, C., Bria, E., et al. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.107444 · Cited by 24
Self-citationErnst, S. M., van Marion, R., Atmodimedjo, P. N., de Jonge, E., Mathijssen, R. H. J., Paats, M. S., de Bruijn, P., Koolen, S. L., von der Thüsen, J. H., Aerts, J. G. J. V., et al. (2024) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2024.04.007 · Cited by 24
Self-citationType I interferon signaling pathway enhances immune-checkpoint inhibition in KRAS mutant lung tumors
Fernández-García, F., Fernández-Rodríguez, A., Torre, C. F., Piñeiro-Yáñez, E., Wang, H., Lechuga, C. G., Callejas, S., Álvarez, R., López-García, A., Esteban-Burgos, L., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2402913121 · Cited by 21
Akamatsu, H., Sakata, S., Azuma, K., Yoshioka, H., Uemura, T., Tsuchiya‐Kawano, Y., Esumi, S., Kurosaki, T., Sato, Y., Sakamoto, T., et al. (2025) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2025.01.006 · Cited by 22
Self-citationEvolution of direct RAS inhibitors: from undruggable target to clinical breakthroughs
Wang, X., Wu, J., Xiao, A., Wang, J., & Tian, J. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02364-0 · Cited by 25
Gadgeel, S. M., Miao, J., Riess, J. W., Moon, J., Mack, P. C., Gerstner, G. J., Burns, T. F., Taj, A., Akerley, W., Dragnev, K. H., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-3947 · Cited by 22
Brambs, C., Horn, L., Hiller, R., Krücken, I., Braun, C., Christmann, C., Monecke, A., & Höhn, A. K. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05306-9 · Cited by 22
Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments
Torres-Jiménez, J., Espinar, J. B., Bote, H., Berjaga, M. Z., Esteban-Villarrubia, J., Fraile, J. Z., & Paz-Ares, L. G. (2024) · Drugs · doi:10.1007/s40265-024-02030-7 · Cited by 24
Self-citationFigarol, S., Delahaye, C., Gence, R., Doussine, A., Cerapio, J., Brachais, M., Tardy, C., Béry, N., Asslan, R., Colinge, J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49360-4 · Cited by 26
Self-citationAXL signal mediates adaptive resistance to KRAS G12C inhibitors in KRAS G12C-mutant tumor cells
Morimoto, K., Yamada, T., Hirai, S., Katayama, Y., Fukui, S., Sawada, R., Tachibana, Y., Matsui, Y., Nakamura, R., Ishida, M., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216692 · Cited by 20
Hochmair, M. J., Vermaelen, K. Y., Mountzios, G., Carcereny, E., Dooms, C., Lee, S., Mórocz, É., Kato, T., Ciuleanu, T., Dy, G. K., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.114204 · Cited by 20
Self-citationWaterhouse, D. M., Rothschild, S. I., Dooms, C., Mennecier, B., Bozorgmehr, F., Majem, M., van den Heuvel, M. H., Linardou, H., Cho, B. C., Roberts‐Thomson, R., et al. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2024.107921 · Cited by 22
Self-citationKRAS-Driven Tumorigenesis and KRAS-Driven Therapy in Pancreatic Adenocarcinoma
Than, M. T., O’Hara, M. H., Stanger, B. Z., & Reiss, K. A. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0519 · Cited by 22
Wankhede, D., Bontoux, C., Grover, S., & Hofman, P. M. (2023) · Diagnostics · doi:10.3390/diagnostics13193043 · Cited by 19
Metastatic brain tumors: from development to cutting‐edge treatment
Tanzhu, G., Chen, L., Ning, J., Xue, W., Wang, C., Xiao, G., Yang, J., & Zhou, R. (2024) · MedComm · doi:10.1002/mco2.70020 · Cited by 19
Shahnam, A., Davis, A. P., Brown, L. J., Sullivan, I., Lin, K., Ng, C. S., Yeo, N., Kong, B. Y., Khoo, T., Warburton, L., et al. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108421 · Cited by 18
Self-citationZhang, F., Wang, B., Wu, M., Zhang, L., & Ji, M. Q. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1509173 · Cited by 20
KRAS mutated NSCLC: past, present, and future directions in a rapidly evolving landscape
Frisch, A., Martin, E., Kim, S. Y., Riess, J. W., Sen, T., & Karim, N. A. (2025) · The Oncologist · doi:10.1093/oncolo/oyaf153 · Cited by 24
Self-citationZhao, R., Yang, S., Xu, W., Jiang, F., Ran, P., Pan, L., Wang, J., Wang, W., Zhao, J., Wang, Y., et al. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03498-9 · Cited by 19
Self-citationFrille, A., Boeschen, M., Wirtz, H. R. W., Stiller, M., Bläker, H., & von Laffert, M. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1357583 · Cited by 18
Attili, I., Corvaja, C., Aliaga, P. T., Signore, E. D., Spitaleri, G., Passaro, A., & de Marinis, F. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.102957 · Cited by 19
Dingemans, A. C., Syrigos, K., Livi, L., Paulus, A., Kim, S., Chen, Y., Felip, E., Griesinger, F., Ohashi, K., Zalcman, G., et al. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108683 · Cited by 17
Self-citationTargeted degradation of oncogenic KRASG12V triggers antitumor immunity in lung cancer models
Li, D., Geng, K., Yuan, H., Gu, J., Kumar, S., Olson, A. T., Kuismi, C. C., Kim, H. M., Pan, Y., Sherman, F., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci174249 · Cited by 18
Liu, Y., Chen, J., Li, X., Fan, Y., Peng, C. Y., Ye, X., Wang, Y. A., & Xie, X. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107577 · Cited by 17
Self-citationXin, S., Wen, M., Tian, Y., Dong, H., Wan, Z., Jiang, S., Meng, F., Xiong, Y., & Han, Y. (2025) · World Journal of Surgical Oncology · doi:10.1186/s12957-025-03701-9 · Cited by 18
Current perspectives of KRAS in non-small cell lung cancer
Harris, E., & Thawani, R. (2024) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2024.101106 · Cited by 17
An updated overview of K-RAS G12C inhibitors in advanced stage non-small cell lung cancer
Tenekeci, A. K., Unal, A. A., Ceylan, F., & Sendur, M. A. N. (2024) · Future Oncology · doi:10.1080/14796694.2024.2407280 · Cited by 16
Daley, B. R., Sealover, N. E., Finniff, B. A., Hughes, J. M., Sheffels, E., Gerlach, D., Hofmann, M. H., Kostyrko, K., LaMorte, J. P., Linke, A. J., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-3256 · Cited by 20
Lung Cancer with Brain Metastasis—Treatment Strategies and Molecular Characteristics
Wang, S., Uriel, M., & Cheng, H. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13237371 · Cited by 17
Yuan, Y., Deng, Y., Jin, Y., Guo, Z., Pan, Y., Wang, C., Wang, Z., Hu, Y., Hua, D., Meng, X., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02315-7 · Cited by 18
Covalent inhibitors of the PI3Kα RAS binding domain impair tumor growth driven by RAS and HER2
Klebba, J. E., Roy, N., Bernard, S. M., Grabow, S., Hoffman, M. A., Miao, H., Tamiya, J., Wang, J., Berry, C., Esparza-Oros, A., et al. (2025) · Science · doi:10.1126/science.adv2684 · Cited by 15
Caughey, B. A., & Strickler, J. H. (2023) · Drugs · doi:10.1007/s40265-023-01980-8 · Cited by 15
Fukuda, A., & Okuma, Y. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-4035 · Cited by 16
Advancements in gene therapies targeting mutant KRAS in cancers
Wang, Y., Bui, T. A., Yang, X., Hutvágner, G., & Deng, W. (2025) · Cancer and Metastasis Reviews · doi:10.1007/s10555-025-10243-9 · Cited by 20
Self-citationYoshimura, A., Horinaka, M., Yaoi, T., Ono, H., Itoh, K., Yamada, T., Takayama, K., & Sakai, T. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02727-2 · Cited by 15
Jabbour, S. K., Kumar, R. N., Anderson, B. M., Chino, J., Jethwa, K. R., McDowell, L. J., Lo, A., Owen, D., Pollom, E. L., Tree, A. C., et al. (2024) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2024.01.010 · Cited by 14
The Retrofit: Lessons From Sotorasib's Dosing Conundrum
Singh, H., Vellanki, P. J., & Pazdur, R. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.24.00310 · Cited by 14
Wu, Z., Luo, M., Hu, H., Jiang, Z., Lu, Y., & Xiao, Z. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06791-x · Cited by 13
Modest, D. P., Fakih, M., Salvatore, L., Esaki, T., Páez, D., Taı̈eb, J., Karamouzis, M. V., Ruíz‐García, E., Kim, T. W., Kuboki, Y., et al. (2025) · The Lancet Oncology · doi:10.1016/s1470-2045(25)00352-3 · Cited by 14
Álvarez-Pérez, J. C., Sanjuán‐Hidalgo, J., Arenas, A. M., Hernández-Navas, I., Benitez‐Cantos, M. S., Andrades, Á., Fariñas, S. C., Lewintre, E. J., Paz-Ares, L. G., Ferrer, I., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-62350-4 · Cited by 15
Self-citationAdvances in Targeted Therapy for Non-Small-Cell Lung Cancer: Current Progress and Future Directions
Peshin, S., Takrori, E., Yazji, J. H., Haque, J., Dharia, A. A., Mithani, M. S., Anum, F., Asfeen, U. Z., Couch, J. K., Donovan, M., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262311517 · Cited by 15
Burns, T. F., Ammakkanavar, N. R., Hollebecque, A., Lee, D. H., Koyama, T., Cassier, P. A., Italiano, A., Han, J., Singhal, N., Takeuchi, S., et al. (2025) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2025.11.018 · Cited by 14
Ghazali, N., Garassino, M. C., Leighl, N. B., & Bestvina, C. M. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251323985 · Cited by 13
Potency and Safety of KRAS G12C Inhibitors in Solid Tumors: A Systematic Review
Zaitouni, S. E., Laraqui, A., Boustany, Y., Benmokhtar, S., Annaz, H. E., Abi, R., Tagajdid, M. R., Kochri, S. E., Bouaiti, E. A., Amine, I. L., et al. (2025) · Clinical Medicine Insights Oncology · doi:10.1177/11795549251331759 · Cited by 13
Skoulidis, F., Li, B. T., Hochmair, M. J., Govindan, R., Vincent, M. D., van der Wekken, A. J., Aransay, N. R., O'Byrne, K. J., Girard, N., Griesinger, F., et al. (2025) · The Oncologist · doi:10.1093/oncolo/oyae356 · Cited by 13
Self-citation50 Years of Progress in NSCLC: A New Fellow’s Guide in the Clinic
Naidoo, J., Niroula, A., Uprety, D., Smeltzer, M. P., Geissen, N. M., Osarogiagbon, R. U., Mino-Kenudson, M. A., Yatabe, Y., Higgins, K. A., Desai, A. P., et al. (2025) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2025.06.028 · Cited by 13
Knoll, N., Masser, S., Bordas, B., Ebright, R. Y., Li, G., Kesar, D., Destefanis, E., Kania, N., Rodriguez, D. J., Jen, J., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-25-1464 · Cited by 14
Porta, C., Pradelli, L., Sicari, E., Castellani, S., Sivakumar, S., Sokol, E. S., Montesion, M., Wieland, T., Rambichler, J., Minari, R., et al. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.107359 · Cited by 12
KRASG12C mutant lung adenocarcinoma: unique biology, novel therapies and new challenges
Moldvay, J., & Tı́már, J. (2024) · Pathology & Oncology Research · doi:10.3389/pore.2023.1611580 · Cited by 15
Ha, H., Lee, H. Y., Kim, J. H., Kim, D. Y., An, H. J., Bae, S., Park, H.-S., & Kang, J. H. (2024) · Cancer Research and Treatment · doi:10.4143/crt.2024.128 · Cited by 14
He, Q., Liu, X., Jiang, L., Liu, P., Xuan, W., Wang, Y., Meng, R., Feng, H., Lv, S., Miao, Q., et al. (2024) · Cancer Biology & Therapy · doi:10.1080/15384047.2024.2441499 · Cited by 13
Self-citationKhan, J., Ghosh, P. K., Bajpai, U., Dwivedi, K., & Saluja, D. (2024) · Discover Oncology · doi:10.1007/s12672-024-01712-8 · Cited by 13
Immunotherapy in Oncogene-Addicted NSCLC: Evidence and Therapeutic Approaches
Foffano, L., Bertoli, E., Bortolot, M., Torresan, S., Carlo, E. D., Stanzione, B., Conte, A. D., Puglisi, F., Spina, M., & Bearz, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26020583 · Cited by 12
WEE1 confers resistance to KRASG12C inhibitors in non-small cell lung cancer
Yamamoto, G., Tanaka, K., Kamata, R., Saito, H., Yamamori-Morita, T., Nakao, T., Liu, J., Mori, S., Yagishita, S., Hamada, A., et al. (2025) · Cancer Letters · doi:10.1016/j.canlet.2024.217414 · Cited by 11
Developments and challenges in hit progression within fragment-based drug discovery
Grosjean, H., & Biggin, P. C. (2026) · Nature Communications · doi:10.1038/s41467-026-68941-z · Cited by 15
Luo, J., Florez, N., Donnelly, A., Lou, Y., Lu, K., Ma, P. C., Spira, A. I., Ryan, D. L., & Husain, H. (2024) · JCO Precision Oncology · doi:10.1200/po.23.00644 · Cited by 12
Resistance to KRAS inhibition in advanced non-small cell lung cancer
Sreter, K. B., Catarata, M. J., von Laffert, M., & Frille, A. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1357898 · Cited by 12
Zhang, H., Zhang, Y., Zhu, Y., Dong, T., & Liu, Z. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1387345 · Cited by 14
Extrahepatic Cholangiocarcinoma: Genomic Variables Associated With Anatomic Location and Outcome
Preston, W. A., Drill, E. N., Boerner, T., Gelfer, R., Harding, J. J., O'Reilly, E. M., Cercek, A., Abou‐Alfa, G. K., Park, W., Balachandran, V. P., et al. (2024) · JCO Precision Oncology · doi:10.1200/po.24.00206 · Cited by 12
Recent advances in therapeutic targeting of the KRAS pathway in cancer
Hitchen, N., Williams, S., & Desai, J. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108889 · Cited by 15
Multiple signaling pathways in the frontiers of lung cancer progression
Liu, H., Zhou, D., Ou, Y., Chen, S., Long, Y., Yuan, T., Li, Y., & Tan, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1593793 · Cited by 11
Kruithof, P. D., de Beer, Y. M., Gulikers, J. L., Stolk, L. M., Hendriks, L. E. L., Croes, S., & van Geel, R. M. J. M. (2023) · Journal of Chromatography B · doi:10.1016/j.jchromb.2023.123918 · Cited by 11
Dose optimization of sotorasib: Has the burden of proof for the labeled dose been met?
Popat, S., & Ratain, M. J. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.115044 · Cited by 11
Murciano-Goroff, Y. R., Hollebecque, A., Heist, R. S., Cassier, P. A., Han, J.-Y., Kim, S. Y., Sabari, J. K., Tosi, D., Sacher, A., Burns, T. F., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-69943-7 · Cited by 13
Self-citationDrosten, M., & Barbacid, M. (2025) · Molecular Oncology · doi:10.1002/1878-0261.70149 · Cited by 11
Current status of molecular diagnostics for lung cancer
Имянитов, Е. Н., Преображенская, Е. В., & Орлов, С. В. (2024) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2024.00244 · Cited by 15
Koban, M. U., Hartmann, M., Amexis, G., Franco, P., Huggins, L., Shah, I., & Karachaliou, N. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-0741 · Cited by 10
Vitale, A., Mastrantoni, L., Russo, J., Giacomini, F., Giannarelli, D., Duranti, S., Vita, E., Nero, C., D’Argento, E., Pasciuto, T., et al. (2024) · JCO Precision Oncology · doi:10.1200/po.24.00297 · Cited by 12
Yuan, F., Jiang, Y., Yang, L., Lu, D., Li, N., Zhang, Q., Yang, H., Qin, H., Zhang, J., Gou, X., et al. (2025) · Journal of drug targeting · doi:10.1080/1061186x.2025.2453730 · Cited by 11
Somatic Genomic Profiling of Pancreatic Ductal Adenocarcinomas From a Diverse Cohort of Patients
Riner, A. N., Velazquez-Villarreal, E. I., Rajpara, S., Qian, J., Jin, Y., Loza, D., Akki, A. S., Herremans, K. M., Raj, R., Williams, T. M., et al. (2025) · Pancreas · doi:10.1097/mpa.0000000000002408 · Cited by 8
Wei, K., Sun, T., Feng, X., Yang, C., Liu, Q., & Tang, H. (2025) · BMC Cancer · doi:10.1186/s12885-025-13868-9 · Cited by 10
Wang, Z., Cai, G., Zhu, J., Wang, J., & Zhang, Y. (2025) · Molecular and Clinical Oncology · doi:10.3892/mco.2025.2837 · Cited by 12
Gales, L. N., Păun, M.-A., Butnariu, I., Simion, L., Manolescu, L. S. C., Trifanescu, O. G., & Anghel, R. M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26073123 · Cited by 12
Nondegradative Synthetic Molecular Glues Enter the Clinic
Repity, M. L., Deutscher, R. C. E., & Hausch, F. (2025) · ChemMedChem · doi:10.1002/cmdc.202500048 · Cited by 10
Precision immune regulation in KRAS-mutated cancers: the final piece of the puzzle?
Fu, S., Ma, J., Cai, C., Tan, J., Deng, X., Shen, H., Zeng, S., Chen, Y., & Han, Y. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03444-1 · Cited by 11
Self-citationChmielewska, I., Krawczyk, P. A., Grenda, A., Wójcik-Superczyńska, M., Krzyżanowska, N., Gil, M., & Milanowski, J. (2023) · Cancers · doi:10.3390/cancers15143732 · Cited by 10
Siringo, M., Baena, J., Bote, H., Torres-Jiménez, J., Zurera, M. C., Zugazagoitia, J., & Paz-Ares, L. G. (2023) · Cancers · doi:10.3390/cancers15235505 · Cited by 10
Self-citationPeng, T., Wu, T., Yi, T.-Y., & Wu, A. (2024) · Cancers · doi:10.3390/cancers16213676 · Cited by 9
Advances in the Treatment of Rare Mutations in Non-Small Cell Lung Cancer
Sun, Y., Ma, L., Zhang, X., & Wang, Z. (2024) · OncoTargets and Therapy · doi:10.2147/ott.s487870 · Cited by 10
Hernandez‐Martinez, J., Güijosa, A., Flores‐Estrada, D., Cruz‐Rico, G., Turcott, J. G., Hernández‐Pedro, N., Caballé‐Perez, E., Cardona, A. F., & Arrieta, O. G. (2024) · JCO Global Oncology · doi:10.1200/go-24-00338 · Cited by 14
Wang, X.-D., Lin, J.-H., & Hu, M.-H. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.108164 · Cited by 9
Systemic anti‐cancer therapy and anaesthesia: a narrative review
Weaver, J. M. J., & Patey, S. J. (2025) · Anaesthesia · doi:10.1111/anae.16522 · Cited by 9
Evolution of first versus next-line targeted therapies for metastatic non-small cell lung cancer
Waliany, S., Lin, J. J., & Gainor, J. F. (2025) · Trends in cancer · doi:10.1016/j.trecan.2025.01.005 · Cited by 10
Wislez, M., Mascaux, C., Cadranel, J. L., Thomas, Q. D., Ricordel, C., Swalduz, A., Pichon, E., Veillon, R., Gounant, V., Rousseau-Bussac, G., et al. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115301 · Cited by 9
Wang, P., Sun, X., He, X., Kang, D., Liu, X., Liu, D., Li, A., Yang, G., Lin, Y., Li, S., et al. (2025) · Cancer Research Communications · doi:10.1158/2767-9764.crc-25-0001 · Cited by 9
Self-citationLiu, H., Zhou, C., Lü, J., Liu, Y., Zou, P., Zhu, L., Lei, H.-M., & Han, B. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07687-w · Cited by 9
IGF-1R Inhibitors in Cancer: A Review of Available Evidence and Future Outlook
Guven, D., Ahmed, J., Stephen, B., & Naing, A. (2025) · Critical reviews in oncology/hematology · doi:10.1016/j.critrevonc.2025.104809 · Cited by 10
Vascular malformations: from genetics to therapeutics
Morin, G., Galasso, I., & Canaud, G. (2025) · EMBO Molecular Medicine · doi:10.1038/s44321-025-00344-x · Cited by 9
Melanoma: Pathogenesis and Targeted Therapy
Fu, Y., Liu, J., Mo, Z., Wang, B., Deng, Y., & Jiang, Y. (2026) · MedComm · doi:10.1002/mco2.70566 · Cited by 11
The end of the beginning: progress and next steps in KRAS-mutant non-small-cell lung cancer
Goldberg, S. B., & Herbst, R. S. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00288-x · Cited by 9
Noordhof, A. L., Swart, E. M., Damhuis, R. A. M., Hendriks, L. E. L., Kunst, P. W. A., Aarts, M. J., & van Geffen, W. H. (2023) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2023.100543 · Cited by 10
Bhamidipati, D., & Subbiah, V. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.101591 · Cited by 10
Luo, W. P., Zhu, J., Zhang, W., Yu, A., Zhou, W., & Xu, K. (2023) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2023.2282606 · Cited by 10
RAS and Other Molecular Targets in Pancreatic Cancer: The Next Wave Is Coming
Miller‐Phillips, L., & Collisson, E. A. (2023) · Current Treatment Options in Oncology · doi:10.1007/s11864-023-01096-x · Cited by 10
Equipoise Lost? Trial Conduct Challenges in an Era of Breakthrough Therapies
Fallah, J., Mulkey, F. A., Fiero, M. H., Gittleman, H. R., Song, C. W., Puthiamadathil, J., Amatya, A. K., Agrawal, S., Vellanki, P. J., Suzman, D. L., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco-24-01200 · Cited by 13
Reyes, A. R., Afkhami, M., Massarelli, E., Fricke, J., Mambetsariev, I., Li, X., Velasquez, G., & Salgia, R. (2024) · Clinical Lung Cancer · doi:10.1016/j.cllc.2024.07.010 · Cited by 8
The Impact of Genetic Mutations on the Efficacy of Immunotherapies in Lung Cancer
Lui, K., Cheung, K., Ng, W. W. M., Wang, Y., Au, D. W. H., & Cho, W. C. S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252211954 · Cited by 9
Self-citationAmato, L., Omodei, D., Rosa, C. D., Ariano, A., Capaldo, S., Tufano, C. C., Buono, R., Terlizzi, C., Nardelli, A., Vecchio, V. D., et al. (2024) · Cancers · doi:10.3390/cancers16233941 · Cited by 8
Metadata
- Authors
- de Langen, A. J., Johnson, M. L., Mazieres, J., Dingemans, A.-M. C., Mountzios, G., Pless, M., Wolf, J., Schuler, M., Lena, H., Skoulidis, F., Yoneshima, Y., Kim, S.-W., Linardou, H., Novello, S., van der Wekken, A. J., Chen, Y., Peters, S., Felip, E., Solomon, B. J., Ramalingam, S. S., Dooms, C., Lindsay, C. R., Ferreira, C. G., Blais, N., Obiozor, C. C., Wang, Y., Mehta, B., Varrieur, T., Ngarmchamnanrith, G., Stollenwerk, B., Waterhouse, D., & Paz-Ares, L.
- Affiliations
- Sarah Cannon (US)
- Erasmus MC (NL)
- Henry Dunant Hospital (GR)
- Kantonsspital Winterthur (CH)
- University Hospital Cologne (DE)
- The University of Texas MD Anderson Cancer Center (US)
- Kyushu University Hospital (JP)
- Asan Medical Center (KR)
- Metropolitan Hospital (GR)
- Ospedale San Luigi Gonzaga (IT)
- Centre Hospitalier Universitaire Vaudois (CH)
- Vall d'Hebron Hospital Universitari (ES)
- Peter MacCallum Cancer Centre (AU)
- Emory University (US)
- KU Leuven (BE)
- University of Manchester (GB)
- Centre Hospitalier de l’Université de Montréal (CA)
- Amgen (United States) (US)
- Amgen (Switzerland) (CH)
- Oncology Hematology Care (US)
- Universidad Complutense de Madrid (ES)
- Corresponding author
- Paz-Ares, Luis
- ORCID
- Johnson, Melissa L
- Dingemans, Anne-Marie C
- Mountzios, Giannis
- Pless, Miklos
- Wolf, Jürgen
- Skoulidis, Ferdinandos
- Yoneshima, Yasuto
- Kim, Sang-We
- Linardou, Helena
- Novello, Silvia
- Chen, Yuanbin
- Peters, Solange
- Felip, Enriqueta
- Solomon, Benjamin J
- Ramalingam, Suresh S.
- Dooms, Christophe
- Lindsay, Colin R
- Ferreira, Carlos Gil
- Blais, Normand
- Wang, Yang
- Stollenwerk, Björn
- Waterhouse, David
- Paz-Ares, Luis
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2023-03
- Volume
- 401
- Issue
- 10378
- Pages
- 733-746
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W4319337483
- Cited by
- 619
- References
- 29
- Citations by year
- 2026: 146 · 2025: 196 · 2024: 196 · 2023: 81
- FWCI
- 113.31
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, other-oa)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- HAL (submittedVersion)
- IRIS (submittedVersion)
- Lirias (KU Leuven) (submittedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- SERVAL (Université de Lausanne) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Funders
- Amgen
- Amgen Inc San Francisco
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- sotorasib, docetaxel, KRAS G12C mutation, non-small cell lung cancer, KRAS inhibitors, progression-free survival, second-line therapy, previously treated advanced NSCLC, central nervous system metastasis, treatment safety, oral versus intravenous administration, head-to-head comparison
- MeSH terms
- Docetaxel, Adolescent, Adult, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Mutation, Piperazines, Pyridines, Pyrimidines, Proto-Oncogene Proteins p21(ras), Disease-Free Survival
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
